Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-22
2007-05-22
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S300000, C530S324000, C530S333000
Reexamination Certificate
active
09554531
ABSTRACT:
Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.
REFERENCES:
patent: 5424286 (1995-06-01), Eng
patent: 6506724 (2003-01-01), Hiles et al.
patent: 6924264 (2005-08-01), Prickett et al.
patent: 723694 (1998-01-01), None
patent: WO 9746584 (1997-12-01), None
patent: WO 98/05351 (1998-02-01), None
patent: WO 98/30231 (1998-07-01), None
patent: WO 99/07404 (1999-02-01), None
D'Alessio, et al., “Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons,”J. Clin. Invest.97:133-138 (1996).
Daniel, et al.., “Use of Glucagon in the Treatment of Acute Diverticultis,”Br. Med. J.,3:720 (1974).
Eissele, et al., “Rat gastric somatostatin and gastrin release: Interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide,”Life Sci.55:629-634 (1994).
Eng, et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom,”J. Biol. Chem.267:7402-7405 (1992).
Eng, et al., “Purification and structure of exendin-3, a new pancreatic secretagogue isolated from heloderma horridum venom,”J. Biol. Chem.265:20259-20262 (1990).
Glauser, et al., “Intravenous Glucagon in the Management of Esophageal Food Obstruction,”J. Am. Coll. Emergency Physns.,8:228 (1979).
Goke, et al., “Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)- amide receptor of insulin-secreting β-cells,”J. Biol. Chem.268:19650-19655 (1993).
Malhotra, et al., “Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini,”Regulatory Peptides41:149-156 (1992).
O'Halloran, et al., “Glucagon-like peptide-1 (7-36)-NH2: A physiological inhibitor of gastric acid secretion in man,”J. Endocrinol.126(1):169-173 (1990).
Orskov, et al., “Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable,”Diabetes42:658-661 (1993).
Raufman, et al., “Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas,”J. Biol. Chem.267:21432-21437 (1992).
Scarpignato, et al, “Action of Caerulein on Gastric Emptying of the Conscious Rat,”Arch. int. Pharmacodyn.246:286-294 (1980).
Schepp, et al., “Exendin-4 and exendin-(9-39) NH2: Agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2,”Eur. J. Pharmacol.269:183-191 (1994).
Schjoldager, et al., “GLP-1 (Glucagon-like peptide 1) and truncated GLP-1 fragments of human proglucagon, inhibit gastric acid secretion in humans,”Dig Dis. Sci.34(5):703-708 (1989).
Singh, et al., “Use of 125I-[Y39] exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig,”Regul. Pept.53:47-59 (1994).
Stower, et al., “A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease,”Br. J. Surg.,69:591-592 (1982).
Thorens, “Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1,”Proc. Natl. Acad. Sci.USA 89:8641-8645 (1992).
Wettergren, et al, “Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man,”Digestive Diseases and Sciences, 38(4):665-673 (1993).
Willms, et al., “Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (Noninsulin-dependent) diabetic patients,”J. Clin. Endocrinol. Metab.81(1):327-332 (1996).
Beeley Nigel R.
Prickett Kathryn S.
Kosar Andrew D.
Tsang Cecilia J.
LandOfFree
Exendin agonist peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Exendin agonist peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exendin agonist peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3782887